Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
realSKIN for severe burn wounds
NCT03695939Phase 2Completed
- Sponsor
- XenoTherapeutics
- Start
- Mar 2019
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of realSKIN in burn injury (2 arms), sponsored by XenoTherapeutics. Primary endpoints: Temporary Wound Closure at 14 days and Long-term Safety and Tolerability at 6 months. Started Mar 2019; status: completed.
02
Drugs
realSKIN
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT03695939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695939.